There were moderate correlations between the therapy response of patients with primary ALL and the presence of cytogenetic abnormalities, which correlate with tumorigenesis and the MDR status of leukemia patients [50,51,52]: E2A(19p13.3) (r = 0.31), cMYC(8q24) (r = 0.45), and MYB(6q23.3) (r = 0.33) (Figure 3B). This evidence concerns the gene MYB and leukemia.